Skip to content
Screener

Amphastar Pharmaceuticals AMPH Contract Manufacturing Services — Revenue

Similar metrics at other companies

Zoetis logo
ZTSContract manufacturing & human health — Revenue
$29M-12.1%
Elanco Animal Health Inc. logo
ELANContract Manufacturing — Revenue
$17M+13.3%
Embecta Corp. logo
EMBCContract Manufacturing — Revenue
$2.5M-43.2%
Mannkind logo
MNKDManufacturing Services — Revenue
$2.4M+167%
Biogen logo
BIIBContract manufacturing, royalty and other revenue — Revenue
$183.23M+12.3%
Consolidated Water Company logo
CWCOManufacturing Revenues — Revenue
$1.4M-75.9%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$892.44M-9.1%
Enterprise value$1.36B-6.4%
P/E11.4×+4.1×
P/S1.2×-0.1×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047

Revenues derived from contract manufacturing agreements are recognized when third-party products are shipped to customers. The Company’s accounting policy is to review each agreement involving contract development and manufacturing to determine if there are multiple revenue-generating activities that constitute more than one unit of account. Revenues are recognized for each unit of account based on revenue recognition criteria relevant to that unit. For the three and six months ended June 30, 2026, revenues from contract manufacturing of API were $4.5 million and $7.0 million, respectively. For the three and six months ended June 30, 2025, revenues from contract manufacturing of API were not material to the Company’s condensed consolidated statements of operations.

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's contract manufacturing services — revenue?
Amphastar Pharmaceuticals (AMPH) reported contract manufacturing services — revenue of $4.5M in Q2 2026.
What does contract manufacturing services — revenue mean?
This metric represents the total revenue generated from providing contract manufacturing services to third-party pharmaceutical companies. It reflects the company's ability to leverage its specialized manufacturing infrastructure and technical expertise to produce products for external partners. This revenue stream serves as a key indicator of the company's operational capacity utilization and its role as a strategic manufacturing partner within the broader biopharmaceutical supply chain.

Ask your AI about Amphastar Pharmaceuticals's contract manufacturing services — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude